NAJIT TECHNOLOGIES, INC.
Beaverton, OR · Biotech · Private
HydroVax platform: hydrogen peroxide-based site-directed oxidation technology for producing inactivated virus vaccines with preserved protective epitopes
- Grants
- $9.3M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers | $318,591 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an H2O2-inactivated chikungunya virus vaccine | $2,983,602 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Yellow Fever Vaccine for a Vulnerable Population | $1,248,114 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an H2O2-inactivated chikungunya virus vaccine | $994,841 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Yellow Fever Vaccine for a Vulnerable Population | $996,895 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an H2O2-inactivated chikungunya virus vaccine | $989,109 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Optimization of vaccine antigen for the development of improved influenza | $224,171 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Optimization of vaccine antigen for the development of improved influenza | $224,171 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Yellow Fever Vaccine for a Vulnerable Population | $997,494 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an improved intranasal vaccine against influenza | $275,107 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3200 | TheraCea Pharma LC | — | — |
| 3201 | SAHANE BIOTECH INC | — | — |
| 3202 | HISTONE THERAPEUTICS | — | — |
| 3203 | NAJIT TECHNOLOGIES, INC. | — | — |
| 3204 | OM THERAPEUTICS INC. | — | — |
| 3205 | Anaveon | — | — |
| 3206 | IMETABOLIC BIOPHARMA CORPORATION | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Multivalent Pan-influenza Vaccineapplication
- Inactivating Pathogens And Producing Highly Immunogenic Inactivated Vaccines Using A Dual Oxidation Processapplication
- Inorganic Polyatomic Oxyanions For Protecting Against Antigenic Damage During Pathogen Inactivation For Vaccine Productionapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.